基线无症状疟疾感染与rVSVΔG-ZEBOV-GP埃博拉疫苗免疫原性
在STRIVE试验免疫原性子研究中,506名接种rVSVΔG-ZEBOV-GP的成人中14.6%基线疟原虫PCR阳性。所有时间点抗体几何平均滴度均高于基线,GP-ELISA血清应答率94.1%,PRNT应答率81.5%。基线疟原虫血症者PRNT血清应答比例较低,6和9-12个月应答呈降低趋势。
要点
- 无症状疟疾感染不影响rVSVΔG-ZEBOV-GP疫苗总体免疫应答的持久性。
- 基线疟原虫血症者PRNT血清应答比例较低,6和9-12个月应答呈降低趋势。
- 接种后9-12个月抗体应答仍高于基线。
核心结论
- 有无无症状疟原虫血症的成人对rVSVΔG-ZEBOV-GP均产生稳健且持续9-12个月的免疫应答。
- 基线疟原虫血症者的应答略低。
研究设计与样本
- STRIVE试验免疫原性子研究,506名参与者有至少1次接种后抗体滴度。
- 基线样本用PCR检测疟原虫,499人有结果,73人(14.6%)基线疟原虫血症阳性。
- 接种后1、6、9-12个月采血,用验证过的试验检测抗GP结合抗体和中和抗体。
主要发现
- 1、6、9-12个月所有GP-ELISA和PRNT几何平均滴度均高于基线。
- 94.1%参与者GP-ELISA血清应答(≥2倍升高且≥200 ELISA units/mL),81.5%PRNT血清应答(≥4倍升高),至少一次接种后评估。
- 基线疟原虫血症者PRNT血清应答比例较低,PRNT GMTs及GP-ELISA血清应答和GMTs在6和9-12个月呈降低趋势。
临床怎么用
- 疟疾流行区接种rVSVΔG-ZEBOV-GP仍可产生稳健免疫应答,基线疟疾感染不必作为接种禁忌。
- 对基线疟原虫血症者,需关注其中和抗体应答可能略低。
局限性
- 免疫原性子研究样本量506人,基线疟原虫血症者73人。
- 原文未报告疟原虫血症与应答降低之间差异的统计学显著性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The effect of malaria infection on the immunogenicity of the recombinant vesicular stomatitis virus-Zaire Ebola virus envelope glycoprotein (GP) vaccine (rVSVΔG-ZEBOV-GP) (ERVEBO) is unknown. METHODS: The Sierra Leone Trial to Introduce a Vaccine Against Ebola (STRIVE) vaccinated 7998 asymptomatic adults with rVSVΔG-ZEBOV-GP during the 2014-2016 Ebola epidemic. In STRIVE's immunogenicity substudy, participants provided blood samples at baseline and at 1, 6, and 9-12 months. Anti-GP binding and neutralizing antibodies were measured using validated assays. Baseline samples were tested for malaria parasites by polymerase chain reaction. RESULTS: Overall, 506 participants enrolled in the immunogenicity substudy and had ≥1 postvaccination antibody titer. Of 499 participants with a result, baseline malaria parasitemia was detected in 73 (14.6%). All GP enzyme-linked immunosorbent assay (ELISA) and plaque reduction neutralization test (PRNT) geometric mean titers (GMTs) at 1, 6, and 9-12 months were above baseline, and 94.1% of participants showed seroresponse by GP-ELISA (≥2-fold rise and ≥200 ELISA units/mL), while 81.5% showed seroresponse by PRNT (≥4-fold rise) at ≥1 postvaccination assessment. In participants with baseline malaria parasitemia, the PRNT seroresponse proportion was lower, while PRNT GMTs and GP-ELISA seroresponse and GMTs showed a trend toward lower responses at 6 and 9-12 months. CONCLUSION: Asymptomatic adults with or without malaria parasitemia had robust immune responses to rVSVΔG-ZEBOV-GP, persisting for 9-12 months. Responses in those with malaria parasitemia were somewhat lower.
引用
- Mahon BE, Simon J, Widdowson MA, et al. Baseline Asymptomatic Malaria Infection and Immunogenicity of Recombinant Vesicular Stomatitis Virus-Zaire Ebola Virus Envelope Glycoprotein. J Infect Dis. 2021. PMID: 34013349. doi:10.1093/infdis/jiab243
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。